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Abstract: Immunoglobulins form an important component of the immunological activity 
found in milk and colostrum. They are central to the immunological link that occurs when 
the mother transfers passive immunity to the offspring. The mechanism of transfer varies 
among mammalian species. Cattle provide a readily available immune rich colostrum and 
milk in large quantities, making those secretions important potential sources of immune 
products that may benefit humans. Immune milk is a term used to describe a range of 
products  of  the  bovine  mammary  gland  that  have  been  tested  against  several  human 
diseases. The use of colostrum or milk as a source of immunoglobulins, whether intended 
for the neonate of the species producing the secretion or for a different species, can be 
viewed in the context of the types of immunoglobulins in the secretion, the mechanisms by 
which the immunoglobulins are secreted, and the mechanisms by which the neonate or 
adult  consuming  the  milk  then  gains  immunological  benefit.  The  stability  of 
immunoglobulins  as  they  undergo  processing  in  the  milk,  or  undergo  digestion  in  the 
intestine, is an additional consideration for evaluating the value of milk immunoglobulins. 
This  review  summarizes  the  fundamental  knowledge  of  immunoglobulins  found  in 
colostrum, milk, and immune milk. 
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1. Introduction 
The  topic  of  immunoglobulins  in  milk  immediately  brings  to  mind  the  relationship  between 
mother’s milk, transfer of passive immunity from mother to neonate, and the immature immune system 
of the neonate. Research in this field dates back to the late nineteenth century, however for many 
centuries  herdsmen  have  capitalized  on  the  linkage  between  maternal  immune  status  and  the 
immunological  protection  and  development  of  the  neonate  [1,2].  Immunoglobulins  in  mammary 
secretions come from several sources and represent a history of the antigen exposure of the mother and 
the response of her immune system. Immunoglobulins are transported through the mammary epithelial 
cells by receptor-mediated mechanisms and transferred out of the mammary gland by milk ejection 
during suckling. The immunoglobulins then enter the environment of the gastrointestinal tract of the 
neonate. Although that environment is primarily geared toward digestion to gain nutritional benefit, the 
immunoglobulins  remain  sufficiently  stable  to  provide  protective  benefits  for  the  neonate,  either 
through uptake into the vascular system in the newborn of some species or through immunological 
function in the gastrointestinal tract. The immunoglobulins found in milk and the transfer of passive 
immunity  from  mother  to  neonate  have  been  reviewed  by  many  authors,  with  a  partial  listing 
referenced here [1–18]. 
In addition to the importance of homologous transfer of passive immunity between mother and 
neonate, there is considerable interest in the potential for heterologous transfer of passive immunity, 
such as immunoglobulins obtained from one species and utilized for passive immunity in another 
species. The ability to manipulate the immunological status of animals through vaccination against 
diseases that affect humans and the opportunity to harvest those immunoglobulins in the form of 
colostrum or milk has long been recognized [19,20], and continues to be a topic of interest in both 
animal science and human medicine [13,16,17,21–23]. 
This  review  begins  with  a  summary  of  some  of  the  research  on  what  has  been  termed  
―immune  milk‖  and  then  discusses  various  aspects  of  immunoglobulins  in  mammary  secretions 
(structure,  function,  concentration,  sources,  transport,  species  differences,  and  roles  of 
immunoglobulins).  Finally,  traits  related  to  stability  and  processing  methods  for  collecting  milk 
immunoglobulins are reviewed. 
2. Immune Milk 
2.1. Overview 
One intriguing application of our knowledge about bovine colostral and milk immunoglobulins 
comes  through  the  opportunity  to  provide  passive  immunity  against  diseases  in  other  species, 
especially  in  humans.  The  ability  to  direct  the  cow’s  immune  system  to  produce  antigen-specific 
antibodies that are secreted in colostrum and milk and may be used to provide protection against a 
specific  disease  continues  to  be  an  area  of  interest.  For  example,  the  widespread  consumption  of 
immune milk from cows inoculated against diseases such as avian influenza, SARS, and other human 
respiratory diseases, has been suggested as a potential means of slowing outbreaks of the disease 
before  they  reach  epidemic  levels  [24].  A  number  of  reviews  have  summarized  and  evaluated  
early  attempts  to  develop  and  test  the  use  of  immune  milk  products  to  provide  passive  immune  Nutrients 2011, 3  
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protection [21–23,25–31]. Several immune milk products are available commercially [13,17,22,23,32]. 
Safety issues associated with use of bovine immune milk products for human use have been discussed 
by others [23,33–35]. The discussion below provides some examples of immune milk products and 
their use against some animal and human diseases (sections 2.2–2.7). 
2.2. Homologous Transfer of Passive Immunity 
Secretion of antibodies in breast milk from naturally immunized mothers can provide protection 
against enteric and other diseases in children [11]. For example, elevated concentrations of antibodies 
specific for enteric pathogens, such as Vibrio cholerae, in the mother’s breast milk do not prevent 
colonization with the bacterium in the nursing child, but do seem to protect the infected child from 
developing diarrhea [36]. Breast feeding is associated with a reduced incidence of Campylobacter 
diarrhea in young children compared with children that do not breast feed [37]. In those children that 
are breast fed and do develop diarrhea, the human milk consumed may not contain IgA antibodies 
specific for the common antigen of Campylobacter [37], suggesting a degree of antigen specificity 
contained in the breast milk. 
The idea of immunizing the pregnant animal with the intent of controlling neonatal morbidity and 
mortality is well established [38]. Vaccination or natural immunization of the pregnant cow, ewe or 
sow  against  enterotoxigenic  Escherichia  coli  [38–40]  or  intestinal  viruses  [41,42],  can  provide  a 
degree  of  protection  for  the  newborn.  As  an  example,  while  only  limited  protection  against  viral 
challenge  occurred  in  calves  fed  once  shortly  after  birth  with  a  pooled  colostrum  from  cows 
immunized against bovine rotavirus, a shorter duration of diarrhea was observed [43]. On the other 
hand, calves fed milk supplements with low levels of a similar immune colostrum at each feeding for 
two weeks did have reduced virus sheading and reduced incidence of diarrhea [44]. 
In  primates, immunization of pregnant baboons with a rhesus rotavirus vaccine  increased milk 
immunoglobulin and virus neutralizing titre [45]. Prenatal immunization of pregnant women with a 
single dose of meningococcal vaccine not only increased antigen-specific IgG antibody in the infant’s 
serum  during  the  initial  2–3  months  after  birth,  but  antigen-specific  IgA  in  milk  continued  to  be 
elevated at least up to 6 months [46]. As discussed in section 4, IgG transfer to the offspring in humans 
occurs during late pregnancy and provides the initial systemic source of that immunoglobulin. Infants 
consuming breast milk will primarily be consuming secretory IgA (section 4), which has significant 
protective activity in the intestine, as discussed in section 5.2. 
2.3. Heterologous Transfer of Passive Immunity 
The above examples of homologous transfer of passive immunity set the stage for considering the 
opportunities for heterologous passive transfer. Immune milk products generally are some form of 
protein  product  derived  from  the  colostrum  and/or  milk  of  dairy  cattle.  The  cows  typically  are 
hyperimmunized  against  one  or  more  antigens  representing  pathogens  of  bacterial  or  viral  origin. 
Crude preparations of the immunoglobulin from colostrum or milk may range from essentially no 
alteration of the immunoglobulin concentration in the product to partial immunoglobulin isolation or 
concentration in a whey protein concentrate. Nutrients 2011, 3  
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The  primary  immunoglobulin  in  cow  colostrum  and  milk  is  IgG,  whereas  the  primary 
immunoglobulin in human milk is IgA [1]. Nevertheless, bovine IgG from colostrum or milk can be 
effective as a means of providing passive immunity to protect animals and humans from disease. The 
use of bovine colostral immunoglobulin preparations from immunized cows for disease protection of 
the neonate of other species has been demonstrated in swine [47], and experimental animal models 
such as mice [48,49]. There also are a number of examples of the use of bovine immune milk products 
in the treatment or prevention of human disease, especially in cases where the pathogen acts by way of 
the gastrointestinal tract. When considering these studies, it should always be kept in mind that the 
colostrum  or  milk  preparations  potentially  contain  other  immune  modulating  substances  than 
immunoglobulins, as discussed briefly below (section 6.3). 
The concept of using immune milk derived from hyperimmunized cows for treatment of human 
disease can be traced back to the 1950s and earlier [19,20]. Some of the early efforts in this field 
involved using immune milk products for treatment of rheumatoid arthritis and hay fever [19]. Immune 
milk preparations produced from milk from cows immunized with a heat-killed, lyophilized mixture of 
bacteria found to reside in the human gastrointestinal tract has been studied for the prevention and 
treatment of rheumatoid arthritis, high blood cholesterol, high blood pressure, and oral submucous 
fibrosis [50–53]. On the other hand, most studies on the use of immune milk have examined the 
potential  of  immune  milk  for  prevention  and  treatment  of  infectious  diseases,  particularly 
gastrointestinal disease. 
Even milk that does not come form hyperimmunized cows may in some sense be regarded as 
immune milk. Bovine anti-human rotavirus IgG1 antibodies have been found in raw and pasteurized 
milk  from  cows  that  had  not  been  specifically  immunized  against  that  virus  [54].  Milk  from  
non-immunized  cows  also  has  been  found  to  contain  measurable  antigen-binding  activity  against 
several human pathogenic bacteria [55]. 
2.4. Immune Milk and Diseases Causing Diarrhea 
Several authors have tested the efficacy of immunoglobulin preparations with antibody activity 
against human rotavirus as a means of providing passive immunity to children. For example, children 
consuming a defatted colostrum preparation from cows immunized against a strain of human rotavirus 
had no improvement of symptoms when the infection was established (patients admitted to a hospital 
with rotavirus infection), however the preparation was effective in limiting diarrhea in children when 
consumed prior to the infection [56,57]. In another study, cessation of excretion of rotavirus in the 
stool of infants with acute rotavirus gastroenteritis was correlated with the presence of neutralizing 
activity in the stool after ingestion of a bovine whey protein concentrate from rotavirus-hyperimmunized 
cows [58], although there was not a significant decrease in duration of diarrhea in that study. Other 
studies  have  found  that  treatment  of  children  with  hyperimmune  bovine  colostrum  from  cows 
immunized  with  human  rotavirus  serotypes  reduces  the  duration  and  severity  of  diarrhea  due  to 
rotavirus [59], and can provide significant protection from rotavirus infection [60]. 
Enteropathogenic bacteria have also been the target for development of immune milk. Over 80% of 
childrens’ stools became negative for the E. coli strains used to hyperimmunize the cows that provided 
the source of immunoglobulin in a bovine colostrum/milk immunoglobulin concentrate consumed by Nutrients 2011, 3  
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children for 10 days [61]. Interestingly, only one in nine children treated with the immunoglobulin 
concentrate, and having diarrhea that was associated with E. coli strains which were not used in the 
immunization of the cows, developed negative stools, underscoring the importance of the bacterial 
strain-specificity of the immune product. Consumption of a hyperimmune immunoglobulin concentrate 
with a high antibody titer against a lipopolysaccharide isolated from Shigella flexneri 2a also has been 
shown to provide protection against a challenge with the same strain [62]. However, no difference in 
diarrhea or other symptoms in children with stools positive for S. dysenteriae was found whether 
treated with bovine colostrum from cows immunized against S. dysenteriae or with colostrum from 
cows not hyperimmunized [63]. 
Enterotoxigenic E. coli also is commonly associated with traveler’s diarrhea. Prophylaxis against 
this infection may be achieved by providing passive immunity with immune milk. A bovine whey 
protein  concentrate  from  cows  immunized  with  enterotoxigenic  E.  coli  serotypes  and  consumed  
3-times daily for seven days protected all of the adult volunteers from developing diarrhea after being 
challenged with an enterotoxigenic E. coli strain [64]. In contrast, 90% of the volunteers who received 
control immunoglobulin concentrate prior to challenge developed diarrhea after the E. coli challenge. 
Subsequent studies using IgG isolated from bovine colostrum from cows hyperimmunized against 
specific E. coli colonization factor antigens also have shown protective effects in volunteers challenged 
with colonization factor antigen-bearing enterotoxigenic E. coli [65], however other studies by the 
same group did not demonstrate significant effects of similar milk immunoglobulin products [66]. 
Bovine colostrum concentrate preparations derived from cows that have not been hyperimmunized 
against specific antigens also may provide some benefit via passive immunization for some diseases. 
For  example,  a  commercial  product  which  is  made  from  large  standardized  pools  of  colostrum 
collected from over 100 cows has been used to treat a number of diseases [22,23], including diarrhea 
caused by diarrheagenic E. coli [67]. Similar preparations from non-immunized cows may provide 
protection against bacterial toxins that are the cause of diarrhea in AIDS patients [68]. These studies, 
along  with  the  above  mentioned  study  comparing  colostrum  preparations  from  cows  immunized 
against  S.  dysenteriae  or  non-immunized  cows  [63],  demonstrate  that  bovine  colostrum  contains 
significant antimicrobial properties as a result of natural exposure of the cows to antigens of pathogens 
that may afflict humans. 
2.5. Immune Milk and Dental Caries 
Another example of a potential use for bovine immunoglobulin preparations to control bacterial 
populations comes from studies on dental caries formation [69]. The concept of prenatal immunization 
of the pregnant mother to protect the neonate against dental caries was demonstrated in rats [70].  
In  applications  to  humans,  bovine  whey  preparations  of  colostrum  from  cows  immunized  with  
caries-inducing bacterial strains (Streptococcus mutans and Streptococcus sobrinus), and containing 
over 60% immunoglobulin of which 80% was IgG1, has been used in several studies evaluating its 
effect  on  caries-producing  bacteria.  The  colostral  whey  preparation  reduced  adherence  of 
Streptococcus mutans in vitro and caused aggregation of suspended bacteria [71], as well as inhibited 
glucose  uptake  by  the  test  organism  [72,73].  The  whey  preparation  from  hyperimmunized  cows 
opsonized  bacteria  and  enhanced  in  vitro  phagocytosis  of  bacteria  by  human  leukocytes  [74]. Nutrients 2011, 3  
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Antibodies in the whey preparation remained functional when added to milk that had been treated via 
ultra-high temperature pasteurization or milk that was fermented to extend shelf-life [75]. 
Immune milk from cows hyperimmunized against seven Streptococcus mutans strains reduced the 
recoverable bacterium in plaque samples from volunteers within seven days of initiation of mouth 
rinsing with the whey concentrate product [76]. Mouth rinsing with immune milk collected from cows 
immunized with a fusion protein representing two of the major factors implicated in oral colonization 
by Streptococcus mutans inhibited recolonization of saliva and plaque by that organism [77,78]. 
2.6. Immune Milk and Intestinal Parasites 
Immunodeficiency disorders often are associated with cryptosporidiosis, which can lead to chronic 
malabsorption and weight loss. In a case study of a child with congenital hypogammaglobulinemia, 
severe  vomiting  and  diarrhea  due  to  cryptosporidiosis,  gastric  infusion  with  hyperimmune  bovine 
colostrum from cows immunized with cryptosporidium oocytes resolved the symptoms within a few 
days and oocyts were no longer found in stool samples after about eight days [79]. Similarly, in a child 
with  AIDS  who  had  severe  diarrhea  caused  by  cryptosporidiosis,  administration  of  a  commercial 
hyperimmune bovine colostrum preparation with anticryptosporidial activity improved the diarrhea 
and eliminated the parasite [80]. 
2.7. Immunization to Boost Colostrum and Milk Antibodies 
In the cases where immune milk is collected from cows immunized against one or more pathogens, 
the immunization regimen occurs during the prepartum period of the cow. To put this in perspective 
relative to the lactation cycle of a cow, a brief reminder of that cycle may be helpful. Depending on the 
management system used by a farm, most dairy cattle will have their first calf early in their third year, 
marking the start of their first lactation. The cow will be re-bred about two to three months into 
lactation. Pregnancy is approximately 280 days. At about 2 months before expected calving date, or 
approximately 10 months into lactation, milk removal is halted and the cow is given what is called a 
―dry‖ period. The mammary gland undergoes a process of involution during the early dry period where 
most residual milk components are broken down and resorbed [81]. The mammary gland begins a 
redevelopment phase several weeks prior to calving. Colostrum formation occurs in the days leading 
up to calving, coinciding with the early phase of lactogenesis (initiation of lactation). In the cow, 
lactogenesis begins shortly prior to calving and extends into the first few days postpartum. Colostrum 
collected at the first milking of the cow after calving represents the accumulation of colostral products 
during  the  days  leading  up  to  parturition,  including  immunoglobulins  which  are  at  their  highest 
concentration  in  the  first  milking.  Concentrations  of  immunoglobulins  then  decline  rapidly  in  the 
subsequent several milkings [82]. 
One application for immunization of pregnant or lactating animals comes from the arena of mastitis 
control in cattle. Mastitis is the major disease in dairy cattle and most often is caused by intramammary 
infection [83,84]. Vaccination of cattle against mastitis-causing pathogens has been an area of study 
for many years [85,86]. Optimization of immunization schedules continues to be investigated [87]. 
Effective vaccines against mastitis-causing pathogens can increase antigen-specific immunoglobulins 
in the serum, which in turn can be increased in the mammary secretions. In the case of the J5 E. coli Nutrients 2011, 3  
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bacterin  vaccine,  the  immunization  also  may  be  causing  the  mammary  gland  to  become  
hyper-responsive  to  bacterial  challenge  [88],  reminding  us  that  enhancement  of  antigen-specific 
antibodies in the milk is not the only mechanism by which the vaccine may be having its effect. 
Because the peripartum and early lactation periods are times of high susceptibility of the mammary 
gland  to  mastitis,  many  immunization  schedules  include  prepartum  immunizations  during  the  dry 
period when milk is not removed and the mammary gland undergoes involution. It is also important to 
remember that cattle are generally immunosuppressed during the peripartum period [88,89], potentially 
compromising the impact of immunizations administered just before or just after calving. 
Coliform  mastitis  is  one  of  the  major  types  of  mastitis  in  cattle  [90].  The  more  successful 
vaccination protocols for mastitis control have been with the J5 E. coli bacterin vaccine which is 
administered initially either just before or at the time of drying off [87,91–96]. These typically are 
followed  by  additional  vaccine  doses  approximately  mid-dry  period.  Some  protocols  include  an 
additional immunization within several days after calving [87,91,92,94], while others also continue 
immunizations into the first three months of lactation [87,94]. Attempts to vaccinate against other 
mastitis-causing pathogens have been met with more limited success. Such vaccination protocols range 
from immunizations during the dry period [97], to peak lactation [98], and even late lactation [99]. 
Although most of the immunization protocols used in mastitis control administer the vaccine either 
intramuscularly  or  subcutaneously,  intramammary  immunization  also  can  result  in  an  increase  in 
antigen-specific immunoglobulin in milk, as well as in the serum [100–103]. 
A look across the immunization protocols used in studies to produce many immune milk products 
shows  considerable  variation,  especially  in  the  number  and  timing  of  immunizations.  In  those 
specifically collecting colostrum shortly after calving, multiple immunizations are administered during 
late  pregnancy  when  the  cow  would  be  in  the  dry  period  [56–58,60,61,64,71,72,77,79,104–106]. 
Mammary  secretions  then  are  collected  either  only  at  first  milking  [79],  pooled  from  the  first  
4 to 6 milkings [56,57,72,104], pooled from the first 6 to 10 days after calving [58,61,64,105], or 
collected for longer periods into lactation [77]. Other studies have initiated immunizations during the 
late dry period and then continued vaccinating throughout lactation [50,51,76], or only vaccinating 
during  lactation  [107].  Many  of  these  studies  used  intramuscular  or  subcutaneous  immunization, 
although some also have incorporated intramammary [58,79,105], or intravenous infusion [61]. 
Newer technologies for vaccine development and delivery may further enhance the production of 
immune milk products. Immunization protocols that expose animals to specific antigens may enhance 
humoral  immune  responses  in  the  mammary  gland,  including  peptide-based  vaccines  [108],  and  
DNA-based vaccines [109,110]. Delivery of antigen to the animal can also be achieved with antigen 
encapsulated in biodegradable microspheres [111], and with antigen-release devices [112]. Transgenic 
animals also have been used to produce antigens that then may be used to vaccinate animals against 
viral disease [113]. 
3. Immunoglobulin Structure and Function 
The immunoglobulins, or antibodies, found in colostrum or milk are the same as those found in the 
blood or mucosal secretions. They are a family of proteins with a range of protective bioactivities. 
Immunoglobulins are divided into several classes including IgM, IgA, IgG, IgE, and IgD [114], and Nutrients 2011, 3  
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IgG, IgA and IgM are the major immunoglobulin classes in mammary secretions. IgM is the class that 
appears initially when an organism is exposed to an antigen for the first time (primary infection). IgM 
has  a  low  specificity  and  hence  a  lower  potency  in  defeating  the  infection.  IgA  is  the  major 
immunoglobulin class found in mucosal secretions and prevents mucosal infections by agglutinating 
microbes, whereas IgG is the primary immunoglobulin class found in bovine colostrum and milk. 
Several subclasses of IgG exist, with IgG1 and IgG2 being the major immunoglobulins in serum. All 
monomeric  immunoglobulins  have  the  same  basic  molecular  structure,  being  composed  of 
two identical heavy chains and two identical light chains, with a total molecular mass of approximately 
160 kilodaltons  (for  details  on  immunoglobulin  structure  see  [5,14,16]).  Both  the  heavy  and  light 
chains  have  constant  regions  and  variable regions.  Heavy  and light  chains are  linked  together  by 
disulfide bonds, resulting in the classic Y-shape of the immunoglobulin molecule [114]. The number 
and location of the disulfide bonds is dependent on the class of immunoglobulin. Each immunoglobulin 
molecule has two antigen binding sites which comprise the antigen-binding fragment (Fab). The Fab 
includes the variable amino acid domain. At the other end of the molecule is the constant fragment (Fc) 
which has a constant amino acid sequence among molecules of the same subclass and which confers 
the identity of an immunoglobulin as a particular subclass. The Fc region of the molecule is the region 
that binds to Fc receptors on various cell types. 
In the case of polymeric immunoglobulins, including the polymeric forms of IgA and IgM that are 
found in milk, the monomeric forms of the immunoglobulins are linked together through the covalent 
interaction with a joining (J) chain [114,115]. The result is a dimeric form of IgA and a pentameric 
form of IgM. Binding of these immunoglobulins to the J chain also results in them having several 
special  features,  including:  a  high  valency  of  antigen-binding  sites,  allowing  them  to  agglutinate 
bacteria;  limited  complement-activating  activity,  which  allows  them  to  act  in  a  noninflammatory 
manner; and a high affinity for the polymeric immunoglobulin receptor (pIgR) that is responsible for 
transepithelial transport of IgA and IgM into mucosal secretions such as milk [116]. The pIgR and its 
relationship  to  the  secretory  component  (SC)  associated  with  secretory  IgA  and  secretory  IgM  is 
discussed further below (section 5.2).  
4. Concentrations in Colostrum and Milk—Physiological Conditions 
The  content  of  immunoglobulins  in  colostrum  and  milk  is  highly  dependent  on  the  animal 
species [1,14].  The  same  holds  for  the  relative  proportion  of  the  immunoglobulin  classes.  These 
species differences are adaptations to the reproductive strategies of the animals and the degree of 
maturation of the offspring at birth. Animal species may be divided into three classes [1]: (1) species 
where immunoglobulins are transferred mainly to the fetus via the placenta (humans and rabbits);  
(2) species where offspring are born agammaglobulinemic and immunoglobulin transmission occurs 
via mammary secretions (ungulates such as horses, pigs, cows, and goats); and (3) species where 
immunoglobulins are transferred both via placenta and mammary secretions (rats, mice and dogs). 
These  adaptations  have  several  consequences  both  for  the  composition  of  immunoglobulins  in 
colostrum  and  milk,  and  for  the  role  of  colostrum.  Indeed,  for  animals  like  rats,  mice,  dogs  and 
ungulates, uptake of colostrum of adequate quality and sufficient quantity is important for the offspring 
to boost the systemic immune function in the short term, whereas colostrum consumption in the human Nutrients 2011, 3  
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infant provides more protection for the gastrointestinal tract (see section 6.3). This is reflected in a 
lower total immunoglobulin content in human colostrum as compared to colostrum from the other 
species (Figure 1) [1,3,117]. Human colostrum has a low content of IgG (2%), and the IgG required to 
provide systemic immunity is transferred across the placenta before birth. In contrast, colostral IgG 
content  in  many  other  species  is  typically  greater  than  75%  of  the  total  immunoglobulin  content 
(Figure 1). An additional consequence of different routes of immunoglobulin transmission relates to 
the changes in relative contents of immunoglobulins that occur in the transition from colostrum to milk 
within certain species (Figure 1). For example, the profile of immunoglobulins in human colostrum is 
similar to that found in milk, where the IgA level is high in both colostrum and milk (88–90% of total 
immunoglobulin). This is in contrast to the bovine mammary secretions where the high concentration 
of IgG in colostrum declines rapidly with successive milkings. For animals like rats, mice, dogs and 
ungulates, the role of colostrum and milk immunoglobulins is to provide immune protection both 
systemically and for the gastrointestinal tract, which is reflected in large changes in the profile of 
immunoglobulins during the transition from colostrum to mature milk (Figure 1). Thus, for many 
species the proportion of IgA increases between colostrum and milk. 
Figure 1. Relative distribution of IgG, IgA and IgM in colostrum (outer circle) and in milk 
(inner  circle)  of  five  species.  The  relative  size  of  the  circles  represents  the  overall 
concentration of total immunoglobulins found among the species and the concentrations in 
colostrum vs. milk. Data compiled and calculated from: cow and sheep [1]; human and 
pig [3]; and horse [117]. 
 Nutrients 2011, 3  
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5. Sources and Transport of Immunoglobulins 
5.1. IgG 
Immunoglobulins found in mammary secretions arise from systemic and local sources. In the case 
of IgG in milk, the major portion comes from the serum [14]. While IgG producing plasma cells may 
occur within the mammary tissue, their contribution to the IgG in colostrum is minor compared with 
the IgG derived from the serum. 
Although  limited  paracellular  passage  of  immunoglobulins  may  occur  during  inflammation 
(mastitis), uptake and transport of immunoglobulin across the mammary epithelial barrier is thought to 
occur primarily through an Fc-receptor-mediated process [1,7,118–120]. Immunoglobulins are thought 
to bind to receptors at the basolateral surfaces of the mammary epithelial cell. These receptors are 
specific for the Fc portion of the immunoglobulin molecule. The receptor-bound immunoglobulin is 
internalized via an endocytic mechanism [121], transported to the apical end of the cell and released 
into the alveolar lumen. Recent studies have shed additional light on the details of this process [122]. 
In the case of IgG, the receptor responsible for transcytosis of IgG into colostrum is referred to as 
FcRn, or the neonatal Fc receptor, because it was initially identified in the neonatal rodent intestine as 
the receptor responsible for the specific uptake of maternal IgG [123,124]. The FcRn also has been 
implicated in the trans-placental transport of IgG in humans and other species [125–127], which may 
involve  an  endocytic  and  transcytotic  process  [128].  Since  its  initial  discovery,  FcRn  has  been 
described  in  many  tissues  [122].  The  receptor  is  a  heterodimer  composed  of  a  membrane-bound  
α-chain similar to MHC class-1 molecules and a smaller MHC class-1 protein, β2-microglobulin [129]. 
Binding of IgG to FcRn is pH-dependent, with high affinity binding occurring at acidic pH, but only 
weak  binding  at  neutral  or  basic  pH  [122].  This  observation  suggests  that  IgG  taken  up  by  the 
epithelial  cells  may  bind  to  FcRn  within  an  acidic  environment  in  the  endosomes.  The  precise 
mechanism of transport across the epithelial cell and release into the colostrum or milk remains to 
be demonstrated. 
The half life of IgG in serum is typically longer (1–3 weeks) than that for IgA or IgM (1–2 days), 
and the half-life of IgG2 is slightly longer than for IgG1 [122]. Evidence suggests that IgG2 has a 
higher  affinity  for  FcRn  than  IgG1  [122].  In  bovine  colostrum,  IgG1  is  many  fold  greater  in 
concentration  than  IgG2  [82],  although  they  are  of  approximately  equal  concentrations  in  serum. 
It may be that the majority of the IgG2 taken up by the mammary epithelial cell during colostrum 
formation is not passed on to the alveolar lumen, but rather is recycled back to the extracellular fluid. The 
FcRn is thought to have a major role in the recycling of IgG in various tissues in the body [130–132]. 
That is, IgG that potentially may be lost through various tissues is recycled by the respective cells by 
binding  to  FcRn  and  recycled  back  to  the  blood  or  lymph.  This  is  supported  by  studies  of 
overexpression  of  FcRn  in  transgenic  mice  where  there  is  an  extension  of  the  half-life  of  serum 
IgG [133,134], as well as a boosting of the overall humoral immune response of the mice [135]. 
Localization of FcRn in bovine, sheep and water buffalo mammary tissue indicates that the receptor 
is homogeneously distributed throughout the epithelial cells prior to parturition, but primarily localized 
at the apical surface of the mammary epithelial cells after parturition [136–139]. While this type of 
observation corroborates the conclusion that FcRn plays an important role in IgG transport during Nutrients 2011, 3  
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colostrum formation, at least in ruminant species, the precise meaning of this redistribution of FcRn 
staining in mammary cells remains to be determined. It is also interesting to note that the initial report 
of this distribution pattern in sheep mammary epithelium included the observation that the staining 
pattern became diffuse within the cells during mammary involution [136,137]. Transport of IgG also 
may increase transiently in mammary secretions during involution in cattle [140]. Hormonal and local 
factors  have  been  implicated  in  the  control  of  immunoglobulin  transport  during  colostrum  
formation [32]. 
Haplotypes of the FCGRT gene, coding for the MHC Class I α-chain of FcRn, are associated with 
serum concentrations of IgG in neonatal beef calves [141] and associated with IgG concentrations in 
colostrum of dairy cows [142]. Haplotypes of the β2-microglobulin gene (β2M) also are associated 
with serum IgG concentrations in newborn calves [143]. In estimating mass transfer of IgG1 into 
colostrum in dairy cattle, 10% of cows had mass transfer greater than one standard deviation above the 
mean, perhaps indicating a genetic or hormonal regulation of the variance of transport [144]. Clearly 
there is opportunity for genetic manipulation of IgG transport in the mammary gland to enhance the 
concentrations of immunoglobulins in colostrum and milk. However, it should be remembered that 
serum IgG concentrations in the periparturient cow are already decreased as a result of the extensive 
IgG transport into the colostrum [145], and as indicated above, the cow is in an immunosuppressed 
state during the peripartum period [88,89]. 
5.2. Secretory IgA and IgM 
The other major classes of immunoglobulins transported into colostrum and milk are IgA and IgM. 
Immunoglobulin A is the major immunoglobulin in human colostrum and milk (Figure 1), however it 
is also present in milk of most other species. Colostrum and milk IgA and IgM are found in the form of 
secretory IgA, or sIgA, and sIgM. Much of these are produced by plasma cells in the mammary tissue. 
The plasma cells are part of the gut-associated lymphoid tissue (GALT), the largest immune organ of 
an organism, which includes the Peyer’s patches, lymphoid and myeloid cells in the lamina propria 
and  intraepithelial  lymphocytes  [146,147].  Lymphocytes  from  the  GALT  system  migrate  to  the 
mammary gland and provide a direct link between the antigen exposure response in the mother’s 
mucosal  immune  system,  especially  via  the  enteric  mucosal  immune  system,  and  the  secretory 
immunoglobulin repertoire of the mammary gland [18]. This means that maternal colostrum and milk 
will contain antibodies specific for pathogens that may be encountered by the neonate’s intestine and 
other mucosal tissues [10,18,148], providing a rationale for the observations summarized above that 
bovine colostrum from nonimmunized cows also may afford passive immune protection against human 
pathogens [54,55]. 
The immune connection between the GALT and the mammary gland is of particular interest with 
respect to human milk where the major immunoglobulin is sIgA, which accounts for one of the key 
factors underlying the importance of breast feeding [10]. The immune activation of GALT in the 
human  infant  is  delayed,  and  the  milk  sIgA  and  sIgM  provide  the  neonatal  intestine  a  level  of 
protection through their immune exclusion actions and their anti-inflammatory effects [10,18].  
Transepithelial  transport  of  IgA  and  IgM  across  the  mammary  epithelial  cells  occurs  via  the 
polymeric  immunoglobulin  receptor  (pIgR)  which  is  responsible  for  binding  dimeric  IgA  and Nutrients 2011, 3  
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pentameric IgM in mucosal tissues [149,150]. The polymeric nature of IgA and IgM arises from their 
binding with the J-chain peptide [116]. Only IgA or IgM that contain the J chain have a high affinity 
for pIgR [116,151,152]. In fact, the J chain has been evolutionarily conserved within tetrapods to the 
point where human polymeric IgA can bind to the pIgR from the amphibian Xenopus laevis [152]. 
Polymeric IgA or IgM bound to pIgR is internalized and transported to the apical end of the mammary 
epithelial cell by an endocytic process. The pIgR molecule is cleaved to release a receptor fragment, 
called secretory component (SC), which remains bound to the immunoglobulin molecule [119,149]. 
In the case of pIgR receptor sites that are not occupied by immunoglobulin, the secretory component is 
still  cleaved  from  the  membrane-bound  portion  of  pIgR,  resulting  in  release  of  free  secretory 
component. The secretory component has protective effects of its own, potentially blocking epithelial 
adhesion of enterotoxigenic E. coli and neutralizing the effects of other pathogens [148]. 
Expression of pIgR in the mammary gland is under control of hormones responsible for initiation of 
lactation [153]. Elevated transport of IgA also may occur during mammary gland involution in cattle 
and persist longer into the involution process [140]. 
6. Role of Immunoglobulins in the Intestine 
6.1. Uptake of Immunoglobulins 
Part of the transfer of passive immunity story in mammals involves the timing and location of 
transfer of immunoglobulins from the mother to the offspring, while another part encompasses the fate 
and function of the immunoglobulins once in the neonate [1,7,127]. In humans, intestinal transfer of 
maternal IgG from colostrum is sparse in the neonate and their immune competency is assured by 
transfer via the placenta. In rats and mice, there is FcRn-mediated uptake of IgG from the colostrum 
and milk in the neonate intestine. In ungulate species such as cattle, sheep, goats and pigs, the young 
are born essentially agammaglobulinemic and rely entirely on uptake of colostral immunoglobulins, 
especially IgG, for systemic immune protection.  
The consumption of colostrum by the neonatal calf has significant effects on the gastrointestinal 
tract [154]. The intestinal uptake in the immediate period after birth is transient and nonselective in 
species such as cattle, sheep, goats, swine and others. The intestinal cells become unable to absorb 
macromolecules within 24–36 h after birth probably as a result of developmental processes occurring 
in  the  enterocytes  [155].  The  process  whereby  the  intestinal  cells  gradually  stop  absorbing 
macromolecules is termed ―closure‖. Before closure, the enterocytes will nonselectively absorb large 
molecular weight proteins and other molecules [155]. Macromolecules so transported are released into 
the lamina propria and then are absorbed into the lymphatic or portal circulation. Failure of passive 
transfer of immunity in these species is defined as occurring when a threshold concentration of IgG is 
not  reached  before  closure  occurs,  which  in  the  calf  corresponds  to  serum  IgG  levels  less  than 
10 mg/mL [156]. The maternal IgG in the calf’s blood gradually declines over the initial month after 
birth, and has a half-life of approximately 16 days [157]. Nutrients 2011, 3  
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6.2. Immunoglobulin-Intestinal Interactions 
Milk sIgA is not taken up by the infant’s intestinal mucosa [148,158]. In fact, gut closure in humans 
occurs before birth and little immunoglobulin is absorbed intact in the intestine after birth [148,158]. 
However, the presence of sIgA in the intestinal lumen is part of the protective function of the epithelial 
barrier  in  the  intestine  [159].  Milk  sIgA  in  the  intestine  will  bind  bacteria,  toxins  and  other 
macromolecules, limiting their ability to bind to intestinal cells and thereby be transported through the 
mucosa to the lamina propria to cause a systemic immune response [160]. In adults of a pIgR-deficient 
strain of mice, which do not transport sIgA into the intestinal lumen, there is an increased serum IgA 
and IgG that react with commensal organisms and food antigens [161]. This may be occurring because 
sIgA is not being secreted into the intestinal lumen to participate in its role in immune exclusion  
(see section 6.3), and resulting in an increased uptake of food antigens and microbial antigens from the 
intestinal lumen which pass to the lamina propria and stimulate specific antibody responses [161]. 
Development of the GALT system is dependent on microbial stimulation [148,158]. The  microbe 
binding function of sIgA then modulates the early microbial colonization of the gastrointestinal tract 
and the interaction of those microbes with the developing neonatal immune system [148,158,160]. 
6.3. Intestinal Actions of Colostrum and Milk Immunoglobulins  
From the discussion of immune milk products above it was clear that these products have protective 
effects on neonatal health, as well as infant and adult human health. The exact mechanisms by which 
immune milk products have their effects are less clear and deserve further investigation. Below are 
summarized several perspectives to consider when evaluating the effects of immune milk products and 
the role of immunoglobulins in achieving those effects. 
It  should  be  remembered  that  colostrum  and  milk  not  only  contain  immunoglobulins,  but  
also  contain  a  range  of  antimicrobial  factors  and  factors  that  may  impact  the  immune 
system [10,154,160,162–168].  These  include  the  iron-binding  antimicrobial  protein  lactoferrin, 
antibacterial enzyme lactoperoxidase, antibacterial and lytic enzyme lysozyme, oligosaccharides that 
function as analogues of microbial ligands on mucosal surfaces, antimicrobial heat stable peptides 
(defensins), and soluble CD14. In addition, colostrum and milk contain leukocytes, including activated 
neutrophils, macrophages and lymphocytes. Colostrum also contains cytokines and growth factors that 
may  affect  neonatal  intestinal  development,  as  well  as  intestinal  immune  responses  to  disease  in 
adults [166,169].  The  relative  concentrations  of  these  factors  vary  considerably  among  species. 
Furthermore,  colostrum  provides  a  source  of  energy  which  may  impact  IgG  absorption  in  the 
neonate [170], and provide additional energy for an effective immune response. 
Another point to consider is that, while most macromolecules are degraded by digestive enzymes, 
some portion of macromolecules is transported across the intestine intact, including proteins [171,172]. 
Much  of  the  immunoglobulin  consumed  in  an  immune  milk  can  be  expected  to  be  partially  or 
completely digested (discussed in section 7.3), however some portion of the immunoglobulin will 
remain intact or at least partially intact and capable of binding to an antigen. 
All colostrum and milk will contain some sIgA, even those collected from cattle. The sIgA present 
in these secretions may contribute to the protective effects of immune milk products. Secretory IgA is Nutrients 2011, 3  
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considered to be the primary immunoglobulin responsible for immune protection of mucosal surfaces 
such  as  the  intestine  [158].  Secretory  IgA  and  sIgM,  as  polymeric  forms  of  the  respective 
immunoglobulins, are stabilized by their binding to SC. They have antimicrobial properties such as 
agglutination  of  microbes  and  neutralization  of  viruses,  and  noninflammatory  extracellular  and 
intracellular immune exclusion by inhibiting adherence and invasion of mucosal epithelia [158]. The 
intracellular immune exclusion occurs when sIgA is being transcytosed by the enterocytes and comes 
into contact with viral particles within the endosomic system [15]. Secretory IgA also neutralizes 
pathogens in the intestinal lumen [173]. Bacterial enterotoxins may be neutralized by binding sIgA and 
internalization into intestinal epithelial cells [174].  
In addition, IgA has a major role in the immunosuppressive mechanisms in the intestine that inhibit 
proinflammatory responses to oral antigens, which is part of the oral tolerance mechanisms in the 
intestine [158]. This suppression of the proinflammatory mechanisms is counterbalanced by systemic 
immune factors, including systemic IgG, which may result in inflammation and tissue damage once an 
antigen crosses epithelia barrier to the lamina propria [158].  
After closure, any IgG localized in the lamina propria, whether from systemic sources or from 
uptake from the intestinal lumen, could contribute to proinflammatory responses in the intestine [158]. 
Indeed, post-closure uptake of IgG can occur via the FcRn receptor. FcRn has been identified in the 
human adult intestine [175,176], consistent with the hypothesis that FcRn is involved in IgG recycling 
(discussed  in  section  5.1).  However,  the  transport  of  IgG  across  the  enterocyte  seems  to  be 
bidirectional,  lending  support  to  the  concept  that  IgG  in  the  intestine  is  involved  in  immune 
surveillance and defense of the mucosal lining [176–178]. Intestinal FcRn may deliver IgG-antigen 
immune complexes to the lamina propria for immune processing [158,177], thereby enhancing local 
mucosal immune response.  
On the other hand, functionally intact IgG that remains in the intestinal lumen might be expected to 
bind antigens and participate in protection of the tissue through immune exclusion. The intestinal 
mucus layer does provide an important protective barrier in the interactions of the intestinal tissue with 
microbes  [179].  Interestingly,  an  IgG  Fc  binding  site  has  been  identified  in  association  with  the 
intestinal mucus [180–182]. This IgG Fc binding protein is distinct from the FcRn receptor. The Fc 
binding  protein  may  block  passage  of  IgG-antigen  complexes  to  the  enterocyte  surface,  thereby 
blocking their uptake and transport to the lamina propria, and perhaps allowing the complexes to be 
degraded in the intestinal lumen and excreted [169,182]. 
Consumed  colostrum  also  may  impact  immunological  development  of  the  neonate  [1].  These 
maternal  antibodies  may  then  inhibit  infant  responses  to  vaccine  administration  and  impact 
development of the infant’s immunity [183]. 
7. Immunoglobulin Isolation and Stability 
7.1. Overview 
In the case of dairy animals producing colostrum or milk immunoglobulins for human consumption, 
immunoglobulins are harvested at milking and undergo various types of processing whether it is to 
prolong the shelf-life of the milk, to concentrate or isolate the immunoglobulins from the mammary Nutrients 2011, 3  
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secretion,  or  to  digest  the  milk  in  the  intestine.  Through  such  processing,  immunoglobulins  are 
exposed to a number of conditions that may alter the structure and function of the protein. Some of 
methods used to concentrate or isolate the immunoglobulins include steps that involve exposing the 
protein to heat, acid or pressure which may affect the conformation of the protein, and ultimately the 
immunological activity of the antibody. 
7.2. Isolation of Immunoglobulins from Mammary Secretions 
A  range  of  methods  have  been  used  for  isolation  of  immunoglobulins  from  colostrum  
or  milk.  These  include  traditional  methods  of  ammonium  sulfate  precipitation  and  column 
chromatography [3,5,145,184].  Affinity  chromatographic  methods  used  to  isolate  IgG  include 
lectins [185]; protein A or G chromatography [186,187], and more recently, isolation with protein A/G 
immobilized electrospun polyethersulfone membranes [188]; metal chelate chromatography [189,190]; 
and adsorption with polyanhydride microparticles [191]. The range of detection and quantification 
methods  for  IgG,  most  often  analyzed  by  radial-immunodiffusion  [192]  or  enzyme-linked 
immunosorbant methods [193], are now expanding to include methods that detect multiple proteins, 
such as thermally addressed immunosorbant assays [194], and rapid methods that may be integrated 
into milking systems, such as surface plasmon resonance-based immunosensors [195].  
7.3. Effects of Digestive Enzymes 
Pepsin  is  a  major  proteolytic  enzyme  produced  by  the  stomach.  Pepsin  digestion  of  IgG  
yields  an  F(ab’)2  fragment  that  includes  the  two  antigen-binding  (Fab)  sites  of  the  IgG 
molecule [5,114,196,197].  Intact  immunoglobulin,  F(ab’)2  and  other  antibody  formats  are  being 
exploited in development of antibody therapeutics [198].  
In the small intestine, immunoglobulins are further digested by pancreatic enzymes. One of them, 
trypsin,  preferentially  digests  bovine  IgG1  over  IgM,  whereas  another  enzyme,  chymotrypsin, 
preferentially  hydrolyzes  IgM  over  IgG  [199].  Bovine  IgG1  is  more  susceptible  to  hydrolysis  by 
pepsin than IgG2, while IgG2 is more susceptible to trypsin [200]. 
Immunoglobulins  are  relatively  more  resistant  to  gastrointestinal  digestion  than  other  milk  or 
colostral  proteins.  Upon  ingestion  and  entry  into  the  stomach,  the  caseins  form  a  curd  under  the 
influence of the acidic environment and proteolytic activity. As a consequence, casein is retained in the 
stomach of the neonate longer than the whey proteins, including IgG [201]. In the intestine, the fate for 
the  other  major  whey proteins  is  rapid  digestion  for  α-lactalbumin,  while  β-lactoglobulin is  more 
slowly  digested.  Intestinal  digestion  of  IgG  is  among  the  slowest  of  the  whey  proteins  and  IgG 
provides  the  smallest  proportion  of  amino  acids  to  the  neonate  relative  to  the  other  major  whey 
proteins [201]. In vitro incubations of IgA and IgG with small intestinal content of young lambs have 
shown that IgA is more resistant towards digestion than is IgG [17].  
In adult humans consuming a bovine whey protein concentrate, approximately 59% of IgG and IgM 
was detected by radial immunodiffusion from effluents from the jejunum, while 19% was detected in 
the ileum [202]. These estimates of digestion of immunoglobulin compare with estimates of digestion 
of milk proteins in adult humans which are approximately 42% complete at the end of the jejunum and 
93%  complete  by  the  end  of  the  ileum  [203],  again  underscoring  the  relative  resistance  of Nutrients 2011, 3  
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immunoglobulins to digestion in the gastrointestinal tract. Detectable immunoglobulin in stool samples 
of infants fed the same immune product accounted for 10% of the ingested immunoglobulin [58].  
In adults fed a bovine immunoglobulin concentrate, fecal IgG was typically less than 4% of ingested 
dose [204].  Detectable  IgG  in  the  stool  [204],  or  ileal  effluent  samples  of  adults  [205],  is  not 
significantly  increased  by  prior  treatment  with  a  proton  pump  inhibitor  to  reduce  stomach  acid 
production. However, encapsulation of the immunoglobulin product can significantly increase the IgG 
detectable in the stool [204], although only low levels of IgG are detectable in the ileum of adults 
ingesting  encapsulated  immunoglobulin  [205].  These  studies  suggest  that  degradation  of 
immunoglobulins is occurring throughout the intestinal tract [202]. 
The  primary  structure  of  the  immunoglobulin  found  in  intestinal  effluents  most  likely  is  the 
immunoglobulin Fab or F(ab’)2 fragments found in their stool [58,202], which nevertheless maintains 
its antigen-binding activity, as indicated by the correlation between appearance of the immunoglobulin 
and  the  virus-neutralizing  activity  observed  in  stool  samples  [58].  In  adults  ingesting  bovine  
anti-Clostridium  difficile  immunoglobulins,  toxin-neutralizing  activity  paralleled  the  bovine  IgG 
content in ileal effluent [205], and in stool samples [204]. A pepsin-resistant form of bovine IgG 
representing approximately 10% of colostral immunoglobulin has been isolated with a lectin that binds 
O-linked oligosaccharides [185], indicating that some proportion of IgG in the gastrointestinal tract 
may remain intact. 
7.4. Effects of pH 
The pH of bovine mammary secretions transiently drops at calving (to approximately pH 6.4), then 
increases over several days to pH 6.6 to 6.9 [206], which is the pH characteristic of mature milk. 
Therefore,  bovine  colostrum  is  slightly  more  acidic  than  mature  milk.  Studies  of  isolated 
immunoglobulin stability over a pH range indicate that bovine IgG isolated from milk is stable for 
several hours at 37 °C  when in pH 6–7, however stability is significantly reduced at pH ≤ 3 and  
≥10 [207,208]. The negative effect of pH on IgG stability, even in the range of 4.5–6.5, is enhanced 
under elevated temperature conditions [209,210]. The use of a multiple emulsion to encapsulate milk 
IgG may increase stability of the protein against extreme acidic or alkali conditions, as well as against 
proteolytic degradation [211]. However, emulsification by homogenization may reduce the residual 
IgG content of the emulsion product [211], probably as a result of high shear forces [208]. Ultrasonic 
treatment of isolated IgG also decreases residual IgG content [208]. 
7.5. Effects of Heat Treatment 
Immunoglobulins  are  thermolabile.  Exposure  to  temperatures  of  75  °C   can  reduce  detectable 
isolated bovine IgG by 40% in 5 min, and by 100% at 95 °C  for 15 s [208]. Heat exposure causes 
conformational changes in the IgG molecule [212]. Antigen-binding activity of bovine IgG also is 
reduced  after  heat  treatment  [209,213].  This  is  consistent  with  studies  that  suggest  that  the  
antigen-binding region of the immunoglobulin molecule is more thermolabile than the other regions of 
the  molecule  [209,214].  Detectable  IgG  in  colostrum  or  colostral  whey  also  are  reduced  by  heat 
treatment,  however  at  a  slower  rate  than  for  isolated  IgG.  Thermal  protectants  such  as  sugars  or 
glycerol can increase the stability of isolated IgG to heat treatment [208,215].  Nutrients 2011, 3  
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Many milk processing protocols include heat treatment of the colostrum, milk or whey. Of the 
major immunoglobulin classes in bovine milk, IgG is the most thermostable and IgM is the least 
thermostable [214]. Commercial milk samples that have undergone a typical pasteurization process, 
including skim milk powder, can retain 25–75% of the IgG concentration compared with raw milk, 
while  milk  undergoing  ultra-high  temperature  (UHT)  pasteurization  contains  little  detectable 
IgG [192,216]. Nevertheless, antigen-specific IgG in milk is relatively stable under typical conditions 
of  pasteurization  when  compared  with  that  in  UHT  milk  or  cow  milk-based  infant  formulas  that 
undergo high-temperature processing [54,217].  
Flash-heat treatment of human breast milk, a method recommended by WHO to reduce vertical 
transmission of HIV in resource-poor regions, has minimal effects on milk IgA and antimicrobial 
activity of the milk [218,219]. This method involves placing a jar of milk into a water bath, the water 
bath is heated to boiling, and then the jar of milk is removed and allowed to cool. The milk reaches a 
maximum temperature of 72–73 °C  and is above 56 °C  for over 6 min [218,219]. 
Alternative methods of achieving microbial inactivation may offer a means of avoiding the impact 
of heat treatment on IgG solutions. For example, high voltage pulsed electric fields have been used as a 
nonthermal  processing method  for  pasteurization  in various  foods [220–222]. Pulsed  electric field 
processing also generates heat, however temperature exposure of the fluid is less than 50 ° C, and total 
treatment  time  exposure  is  in  milliseconds  [223].  That  compares  with  more  typical  pasteurization 
process at about 72 °C  for 2 min. Microbial inactivation in bovine IgG solutions as a result of pulsed 
electric fields did not change the secondary structure or the thermal stability of the secondary structure 
of the IgG [224], and antigen-binding activity was unchanged [223]. Another emerging technology that 
may provide a nonthermal microbial inactivation treatment for milk uses exposure to pulsed ultraviolet 
light [225]. 
High-pressure  processing  is  another  non-thermal  method  with  the  potential  for  inactivation  of 
microbial and certain enzymes in food products, thereby extending shelf-life of the product [226]. 
While the high-pressure process also generates heat during the treatment of the sample, lowering the 
initial  temperature  of  the  sample  allows  for  control  of  the  maximum  temperature  reached  to  be 
maintained within a desired range [227]. To be effective in inactivating bacterial spores, high-pressure 
processing needs to be combined with moderate temperature treatment [228]. Moderate to extensive 
loss  of  immunoactivity  of  IgG  may  occur  depending  on  the  conditions  used  for  high-pressure 
processing of colostrum or other IgG-containing fluids [227,229]. High-pressure processing also has 
been used for human breast milk with minimal effect on the milk IgA [230]. 
7.6. Heating Colostrum 
The issue of heating effects on immunoglobulin and colostrum also is important for control of 
various diseases that occur in cattle. Collection and storage of colostrum from dairy cows shortly after 
calving has long been a common procedure. The stored colostrum then is fed to newborn calves to 
assure adequate uptake of IgG for protection of the calf. Several pathogens can be transmitted from 
cow  to  calf  via  colostrum  or  milk  [231].  Colostrum  may  contain  these  pathogens  as  a  result  of 
shedding  from  the  mammary  gland,  contamination  of  the  colostrum  after  harvesting  or  improper 
storage of colostrum prior to feeding calves [231]. One approach to allowing the neonate the benefits Nutrients 2011, 3  
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of colostrum from infected cows is collecting colostrum and batch pasteurization of pooled colostrum 
prior to feeding to the calves [232]. Volume of the batch of pooled colostrum that is pasteurized affects 
measurable IgG concentrations in the colostrum, as well as IgG serum concentrations attained in calves 
after feeding the colostrum [232]. Heat treatment of colostrum at 60 °C  for one to two hours does not 
alter  measurable  IgG  concentrations  or  viscosity  of  the  colostrum,  nor  does  that  treatment  affect 
antibody activity [231,233]. In addition, bacteria inoculated into colostrum prior to a heat treatment of 
60  °C   for  one  hour  are  not  detectable  after  the  heat  treatment  [234].  On-farm  heat  treatment  of 
colostrum (60 °C  for one hour) results in higher concentrations of serum IgG and greater apparent 
absorption efficiency of IgG in new born calves consuming the treated colostrum than consumption of 
raw colostrum [235–237]. 
8. Conclusions 
Colostrum and milk are rich sources of immunoglobulins. These secretions have developed through 
evolution  to  ensure  homologous  transfer  of  passive  immunity  from  mother  to  offspring.  The 
immunoglobulins that are passed from mother to her offspring, whether by transplacental transfer or by 
ingestion of colostrum and milk, can form an important link between the immunological experience of 
the mother and the immune capacity of the newborn. This immunological link also includes many 
immune factors that may be present in mammary secretions other than the immunoglobulins. The 
immunoglobulins in colostrum and milk also provide opportunities to harness their immunological 
function for the benefit of other animals, including humans. Research has demonstrated that bovine 
colostrum and milk, whether or not they are from cows immunized against specific pathogens, provide 
a medium for the heterologous transfer of passive immunity, and may offer disease protection in a 
range of species. New technologies for enhancing efficacy of vaccination, enhancing stability and 
extending shelf-life of the immunoglobulin preparation while minimizing the impact of the processing, 
and extending the effectiveness of the immunoglobulin in the intestine, may enhance future use of 
colostrum and milk based on their potent immunological activity. While the mechanisms by which 
immunoglobulins are transferred from mother to neonate and their role in the neonate have become 
well  documented,  additional  research  is  needed  to  clarify  the  mechanisms  of  action  of  the 
immunoglobulins  derived  from  milk  or  colostrum when  used in animals that are developmentally  
more mature. 
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